Vascepa Capsule
NDC Package 52937-005-20

11-digit billing NDC: 52937000520 · Billing unit: EA · 120 EA per package

Package Information

Vascepa (icosapent ethyl) capsules is vASCEPA® (icosapent ethyl) is indicated:as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (≥ 150 mg/dL) and established cardiovascular disease ordiabetes mellitus and 2 or more additional risk factors for cardiovascular disease.as an adjunct to diet to reduce TG levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia.Limitations of Use:The effect of VASCEPA on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined. This formulation utilizes a capsule delivery system. Marketed by Amarin Pharma Inc., this product is identified by NDC 52937-005 and is authorized under FDA application NDA202057.

Identification & Billing

NDC Package Code
52937-005-20
Package Description
120 CAPSULE in 1 BOTTLE
Product Code
11-Digit Billing Format
52937000520
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
120 EA
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Vascepa
Non-Proprietary Name
Icosapent Ethyl
Substance Name
Icosapent Ethyl
Dosage Form
Capsule - A solid oral dosage form consisting of a shell and a filling. The shell is composed of a single sealed enclosure, or two halves that fit together and which are sometimes sealed with a band. Capsule shells may be made from gelatin, starch, or cellulose, or other suitable materials, may be soft or hard, and are filled with solid or liquid ingredients that can be poured or squeezed.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Usage Information
VASCEPA® (icosapent ethyl) is indicated:as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (≥ 150 mg/dL) and established cardiovascular disease ordiabetes mellitus and 2 or more additional risk factors for cardiovascular disease.as an adjunct to diet to reduce TG levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia.Limitations of Use:The effect of VASCEPA on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined.

Regulatory & Marketing

Labeler Name
Amarin Pharma Inc.
Product Type
Human Prescription Drug
FDA Application #
NDA202057
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
12-05-2025
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 52937-005-20 identifies a specific commercial package of 120 capsule in 1 bottle of Vascepa, a human prescription drug labeled by Amarin Pharma Inc.. This product is billed for "EA" each discreet unit and contains an estimated amount of 120 billable units per package. This capsule is formulated for oral use and contains icosapent ethyl as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Amarin Pharma Inc. on December 05, 2025. The current certification is valid through December 31, 2027.

How is this Amarin Pharma Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 52937000520. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 120 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
52937-005-20
11-Digit CMS (5-4-2)
52937-0005-20

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.